Endothelial progenitor cell: a blood cell by many other names may serve similar functions.
Endothelial progenitor cell: a blood cell by many other names may serve similar functions.
复制标题
DOI：
10.1007/s00109-013-1002-8
复制
发表时间：
2013-03
影响因子：
4.7
通讯作者：
Yoder, Mervin C.
中科院分区：
文献类型：
--
作者：
Yoder, Mervin C.
内皮祖细胞（EPC）生物学领域自产生作为一系列人类临床疾病的潜在修复细胞疗法的巨大前景以来已经接近十五年了。科学家和临床医生以相当快的速度从分离和表征 EPC 生物学特性的基础研究转向心血管疾病啮齿动物模型系统的临床前 EPC 治疗研究，以及将 EPC 或骨髓来源的细胞输送到选定的人类受试者中（综述）。在某些疾病环境中，患者从输注的 EPC 或骨髓源性细胞中获益已被记录，尽管可能没有达到临床前动物模型系统结果所希望或预测的程度。在大多数人类临床试验中，自体骨髓单核细胞已被注入心血管疾病患者体内，试图提供某些假定的 EPC 亚群来改善缺血性损伤。为了对迄今为止的进展提供一些看法，本次综述首先将重点介绍过去 10 年来 EPC 定义的主要澄清，以及这些信息如何指导患者使用的骨髓子集的选择发生变化。为了更好地理解造血细胞在血管修复中所发挥的作用，我们将概述小鼠和人类的造血层次结构，并识别那些表现出促血管生成活性的亚群。这一观点可能有助于读者思考 HSC 和祖细胞作为细胞治疗剂的发现和应用的重要里程碑，而这些里程碑在 EPC 领域尚未得到充分探索。该综述将列出一系列需要解决的问题，以便为参与血管内皮修复和替换的细胞提供更加定量和可定义的命名法。本综述不会讨论由常驻或循环内皮细胞或内皮集落形成细胞组成的 EPC 在正常或病理条件下参与血管修复和再生的作用（综述）。
The field of endothelial progenitor cell (EPC) biology is approaching a decade and a half since generating substantial promise as a potential reparative cell therapy for a spectrum of human clinical disorders. With considerable speed, scientists and clinicians moved from basic studies of isolating and characterizing the biologic properties of EPCs, to pre-clinical EPC treatment studies in rodent model systems of cardiovascular disease, and to the delivery of EPC or marrow-derived cells into selected human subjects (reviewed in). In some disease settings, patient benefits from the infused EPC or marrow-derived cells have been documented, though perhaps not to the extent hoped for or predicted by the results in the preclinical animal model systems. In most human clinical trials, autologous bone marrow mononuclear cells have been infused into patients with cardiovascular disease in an attempt to provide certain presumed EPC subsets to ameliorate ischemic insult. To provide some perspective on the advances to date, this review will begin by highlighting the major clarifications in EPC definitions that have occurred over the past 10 years and how this information has instructed changes to the selection of bone marrow subsets for patient use. To bring perspective to the increased appreciation of the roles played by hematopoietic cells in vascular repair, we will provide an overview of the hematopoietic hierarchy in mouse and man and identify those subsets that display proangiogenic activities. This perspective may help the reader consider crucial milestones in the discovery and application of HSC and progenitor cells as a cell therapeutic that have not been well explored in the EPC field. The review will conclude with a list of issues that need to be addressed to permit a more quantitative and definable nomenclature for the cells that participate in vascular endothelial repair and replacement. This review will not address the role of those EPC comprised of resident or circulating endothelial cells or endothelial colony forming cells involved in vascular repair and regeneration under normal or pathological conditions (reviewed in).
登录
查看更多内容
影响因子：
23.9
作者：
Butler JM;Nolan DJ;Vertes EL;Varnum-Finney B;Kobayashi H;Hooper AT;Seandel M;Shido K;White IA;Kobayashi M;Witte L;May C;Shawber C;Kimura Y;Kitajewski J;Rosenwaks Z;Bernstein ID;Rafii S
通讯作者：
Rafii S
影响因子：
56.9
作者：
Asahara, T;Murohara, T;Isner, JM
通讯作者：
Isner, JM
影响因子：
6.4
作者：
Davidoff, AM;Leary, MA;Vanin, EF
通讯作者：
Vanin, EF
影响因子：
5.2
作者：
de Wynter, EA;Buck, D;Testa, NG
通讯作者：
Testa, NG
影响因子：
64.8
作者：
BECKER, AJ;TILL, JE;MCCULLOCH, EA
通讯作者：
MCCULLOCH, EA